Sanofi (NASDAQ: SNY) reported Q3 EPS of EUR2.55, EUR1.17 better than the analyst estimate of EUR1.38. Revenue for the quarter came in at EUR11.96 billion versus the consensus estimate of EUR13.2 billion.

OUTLOOK

Full-year 2023 business EPS guidance reiterated

Sanofi expects 2023 business EPS(1) to grow mid single-digit(2) at CER, barring unforeseen major adverse events. Applying average October 2023 exchange rates, the currency impact on 2023 business EPS is estimated between -6.0% to -7.0%. This guidance includes approximately €400 million of expected one-off COVID vaccine revenues in the fourth quarter.

For earnings history and earnings-related data on Sanofi (SNY) click here.